251 related articles for article (PubMed ID: 18511808)
1. t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression.
Okumura AJ; Peterson LF; Okumura F; Boyapati A; Zhang DE
Blood; 2008 Aug; 112(4):1392-401. PubMed ID: 18511808
[TBL] [Abstract][Full Text] [Related]
2. Pontin is a critical regulator for AML1-ETO-induced leukemia.
Breig O; Bras S; Martinez Soria N; Osman D; Heidenreich O; Haenlin M; Waltzer L
Leukemia; 2014 Jun; 28(6):1271-9. PubMed ID: 24342949
[TBL] [Abstract][Full Text] [Related]
3. The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes.
Bakshi R; Zaidi SK; Pande S; Hassan MQ; Young DW; Montecino M; Lian JB; van Wijnen AJ; Stein JL; Stein GS
J Cell Sci; 2008 Dec; 121(Pt 23):3981-90. PubMed ID: 19001502
[TBL] [Abstract][Full Text] [Related]
4. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE
Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037
[TBL] [Abstract][Full Text] [Related]
5. Use of the polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21).
Kwong YL; Chan V; Wong KF; Chan TK
Cancer; 1995 Feb; 75(3):821-5. PubMed ID: 7828132
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia.
Li Y; Wang H; Wang X; Jin W; Tan Y; Fang H; Chen S; Chen Z; Wang K
Blood; 2016 Jan; 127(2):233-42. PubMed ID: 26546158
[TBL] [Abstract][Full Text] [Related]
7. AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.
Dunne J; Gascoyne DM; Lister TA; Brady HJ; Heidenreich O; Young BD
Cancer Res; 2010 May; 70(10):3985-95. PubMed ID: 20460523
[TBL] [Abstract][Full Text] [Related]
8. ZFP36L2, a novel AML1 target gene, induces AML cells apoptosis and inhibits cell proliferation.
Liu J; Lu W; Liu S; Wang Y; Li S; Xu Y; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Leuk Res; 2018 May; 68():15-21. PubMed ID: 29518627
[TBL] [Abstract][Full Text] [Related]
9. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group.
LaFiura KM; Edwards H; Taub JW; Matherly LH; Fontana JA; Mohamed AN; Ravindranath Y; Ge Y;
Oncogene; 2008 Aug; 27(36):4933-42. PubMed ID: 18469864
[TBL] [Abstract][Full Text] [Related]
11. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.
Guo C; Li J; Steinauer N; Wong M; Wu B; Dickson A; Kalkum M; Zhang J
J Biol Chem; 2020 Mar; 295(13):4212-4223. PubMed ID: 32071087
[TBL] [Abstract][Full Text] [Related]
13. t(8;21;14)(q22;q22;q24) is a novel variant of t(8;21) with chimeric transcripts of AML1-ETO in acute myelogenous leukemia.
Ishida F; Ueno M; Tanaka H; Makishima H; Suzawa K; Hosaka S; Hidaka E; Ishikawa M; Yamauchi K; Kitano K; Kiyosawa K
Cancer Genet Cytogenet; 2002 Jan; 132(2):133-5. PubMed ID: 11850074
[TBL] [Abstract][Full Text] [Related]
14. Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.
Ahn EY; Yan M; Malakhova OA; Lo MC; Boyapati A; Ommen HB; Hines R; Hokland P; Zhang DE
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17103-8. PubMed ID: 18952841
[TBL] [Abstract][Full Text] [Related]
15. [Genomic distribution of AML1-ETO fusion protein binding sites].
He MM; Shi JT; Zhu XH; Jin W; Wang P; Zhang J; Wagn KK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):553-8. PubMed ID: 20561400
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of minimal residual disease in acute myeloid leukemia with t(8;21)(q22;q22).
Zhang L; Li Q; Li W; Liu B; Wang Y; Lin D; Zhou C; Li C; Wang J; Mi Y
Int J Hematol; 2013 Jun; 97(6):786-92. PubMed ID: 23613269
[TBL] [Abstract][Full Text] [Related]
17. AML1-ETO inhibits acute myeloid leukemia immune escape by CD48.
Wang Z; Guan W; Wang M; Chen J; Zhang L; Xiao Y; Wang L; Li Y; Yu L
Leuk Lymphoma; 2021 Apr; 62(4):937-943. PubMed ID: 33225787
[TBL] [Abstract][Full Text] [Related]
18. The AML1/ETO fusion protein activates transcription of BCL-2.
Klampfer L; Zhang J; Zelenetz AO; Uchida H; Nimer SD
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14059-64. PubMed ID: 8943060
[TBL] [Abstract][Full Text] [Related]
19. RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.
Ptasinska A; Pickin A; Assi SA; Chin PS; Ames L; Avellino R; Gröschel S; Delwel R; Cockerill PN; Osborne CS; Bonifer C
Cell Rep; 2019 Sep; 28(12):3022-3031.e7. PubMed ID: 31533028
[TBL] [Abstract][Full Text] [Related]
20. Chaperonin TRiC/CCT Modulates the Folding and Activity of Leukemogenic Fusion Oncoprotein AML1-ETO.
Roh SH; Kasembeli M; Galaz-Montoya JG; Trnka M; Lau WC; Burlingame A; Chiu W; Tweardy DJ
J Biol Chem; 2016 Feb; 291(9):4732-41. PubMed ID: 26706127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
